Video of LIGHT system and testing facilities

RNS Number : 8887R
Advanced Oncotherapy PLC
15 December 2016
 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Video of LIGHT system and testing facilities

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a new video is available on the Company's website providing an inside look at the groundbreaking technical development of the LIGHT system at its testing facility in Geneva.

 

The video can be viewed here: www.avoplc.com

 

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "This latest video provides an excellent insight into the considerable technical progress that has been made in developing our first LIGHT system, the importance of our international partners in this collaboration and the critical involvement of CERN's expertise in applying their knowhow to the treatment of cancers by Proton Beam Therapy. Our development work is making great strides, as demonstrated by the integration of our proton source and Radio Frequency Quadruple (RFQ) and the high power testing of our proprietary modular accelerating units, the Side Coupled Drift Tube Linacs (SCDTL) and Coupled Cavity Linacs (CCL). We will continue to update shareholders with further progress."

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr Michael Sinclair, Executive Chairman

Nicolas Serandour, CEO

Tel: +44 20 3617 8728



   Stockdale Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten




   Stifel Nicolaus Europe (Joint Broker)

Tel: +44 20 7710 7600

Jonathan Senior / Ben Maddison




   Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001



About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALLFVDFTLSLIR
UK 100

Latest directors dealings